Collaboration augments full-featured
central site model with additional research services and technology
to widen recruitment access and improve the site and patient
experience
KING OF PRUSSIA, Pa. and
CARY, N.C., June 25,
2024 /PRNewswire/ -- United BioSource LLC (UBC), a
leading provider of evidence development solutions, and
Thread®, a leading decentralized research,
electronic clinical outcome assessment (eCOA) and consulting
services provider, today announced the expansion of their SitePlus
solution. This joint offering, the outcome of a successful six-year
working relationship, has provided early recruitment and retention
success for biopharma customers since its March 2023 launch. UBC and Thread have now
expanded the solution to offer additional central site services and
technology features for both post-approval research and Phase
II/III interventional clinical trials.
SitePlus provides a next-generation research model that can be
initiated from initial study design and launch or added alongside
any ongoing Phase II-IV study nationwide. SitePlus offers a central
site model which extends the reach of sites and widens the
addressable patient population. The solution leverages a
centralized technology platform to accelerate patient recruitment,
facilitate home health engagement, securely capture data, and
enable superior patient retention.
SitePlus combines UBC's industry leading late-stage research
solutions with Thread's technology to empower central site study
designs focused on patients while improving the research experience
for all participating sites. It further enables biopharma sponsors
to contract with UBC as a central research center inclusive of
investigator and study coordinating center concierge support
services. SitePlus connects UBC's central principal investigator,
home health, and patient coordinating center expertise with
Thread's unified technology platform and consulting services for
data capture, virtual visits, and optimized patient engagement.
"Study designs that rely exclusively on brick-and-mortar site
models can benefit from the enhancements SitePlus offers to help
meet their patient enrollment and retention goals," said
Bekki Bracken Brown, President &
Chief Executive Officer, UBC. "Studies leveraging a hybrid approach
have seen success in reaching a more representative patient
population, faster, and maintaining patient engagement. The Thread
technology platform supports our central site offering by enabling
a more flexible approach to patient recruitment and engagement and
strengthens the return on evidence generation for our customers.
"
UBC and Thread's enterprise collaboration continues to enrich
UBC's modernized study designs and eCOA solutions that enable
patient-centered research studies to be conducted in the clinic, in
the home, and on-the-go.
"Based on strong early results with SitePlus for our joint
customers, we are excited to expand its features to offer solutions
in both interventional and post-approval research studies," said
Thread Co-Founder and CEO John
Reites. "We appreciate UBC's continued partnership and the
feedback from our biopharma customers to add more value to this
important innovative offering's market growth."
Learn more about SitePlus at www.AddSitePlus.com
About UBC
United BioSource LLC (UBC) is the leading
provider of evidence development solutions with expertise in
uniting evidence and access. UBC helps biopharma mitigate risk,
address product hurdles, and demonstrate safety, efficacy, and
value under real-world conditions. Underpinned by our scientific
expertise, data and analytics, and innovative technologies, we
offer our customers flexible solutions generating the relevant
real-world data necessary to make more informed decisions earlier,
meet stakeholder requirements, and, ultimately, drive better
patient outcomes. For additional information,
visit www.ubc.com.
About Thread
Thread's® purpose is to
leverage its decentralized research platform to enable
studies for everyone, everywhere. The company's uniquely combined
clinical research technology and consulting services help life
science organizations to design, operate, and scale next-generation
research studies and electronic clinical outcome assessments (eCOA)
programs for participants, sites, and study teams. Through its
comprehensive platform and scientific expertise, Thread empowers
studies to be accessible, efficient, and centered on the patient.
Backed by health care investors Water Street Healthcare Partners
and JLL Partners, Thread is recognized as a leader by Everest
Group's Decentralized Clinical Trial Product PEAK
Matrix® Assessment 2021/2022 and positioned in the
Leader's Category of the 2022 IDC MarketScape for R&D
Decentralized Clinical Trial Technology Solutions
Vendor Assessment 2022. Visit Threadresearch.com to learn
more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ubc-and-thread-expand-siteplus-offering-and-active-studies-with-biopharma-sponsors-to-optimize-evidence-generation-302173322.html
SOURCE UBC; Thread